ASTANA (TCA) — Domestically produced drugs account for 20 percent of the pharmaceutical market of Kazakhstan, the official website of the Prime Minister of Kazakhstan reported citing Deputy Chairman of LLP SK-Pharmacy Maxim Kasatkin.
“Currently, the share of domestic medicines on the market is about 20 percent,” Kasatkin told a media briefing late in December.
“If in 2010 the volume of domestic procurement of medicines amounted to 5 billion tenge, today the figure has reached 19 billion tenge. In particular, production of anti-AIDS drugs has been localized,” he added.
The official said that in the future the number of drugs produced in Kazakhstan will gradually increase.
According to him, within the framework of the single market of drugs of the Eurasian Economic Union, Kazakhstan’s pharmaceutical industry will get a new impetus to its development. In particular, rules concerning the registration of medicines will be harmonized.
“Companies will thus be able to get a single sign-on, which operates in all countries of the Eurasian Economic Union and thus opens a huge market of more than 180 million people,” Kasatkin said.
Kasatkin also said that the pharmaceutical market in Kazakhstan had amounted to about 350 billion tenge last year.
According to Research and Markets’ “The Pharmaceutical Market: Kazakhstan” report, Kazakhstan’s pharmaceutical market remains the most accessible, transparent and, from a legislative point of view, progressive in Central Asia.
The country’s government is in the middle of implementing an industrial development policy for pharmaceuticals and three of the top five producers – Chimpharm, Nobel and Global Pharm – are now controlled by foreign investors.
